Tradestie Institutional Equity Comparison Engine
COCP vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
COCP N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner
CLYM
Op Margin -3063.6% vs 0.0% ยท YoY +26.9% vs +0.0%
Momentum & Technical Winner
CLYM
1Y -1.5% vs +407.4% ยท 52W Pos 20% vs 48%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.82% 1D
Market Cap
$18.9M
1M Return
+7.23%
1Y Return
-1.46%
Forward P/E
N/M
Unified AI Score
38.7 / 100
SELL
Tech 25.0
Fund 43.0
Flow 50.0
Mom 54.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap
$608.5M
1M Return
-0.92%
1Y Return
+407.37%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
COCP -1.46%
CLYM +407.37%
Spread: +408.83 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
COCP TTM Op. Margin: -3063.6%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COCP vs CLYM. Trailing 12-month operating profitability (COCP -3063.6% vs CLYM 0.0%) and valuation multiples (COCP N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | COCP | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $18.9M | $608.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +26.9% | +0.0% | Higher Growth | COCP |
| Operating Margin (TTM) Profitability | -3063.6% | 0.0% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -311.7% | -29.3% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 20% ($1โ$2) | 48% ($2โ$18) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 0.97ฮฒ ยท 55% Vol | 1.52ฮฒ ยท 112% Vol | Lower Realized Risk | COCP |
| Unified Institutional Score Composite Signal | 38.7 / 100 (SELL) | 45.7 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full COCP vs CLYM Buy Guide
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither COCP nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.